Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions

de, Oliveira Ferreira Anderson; Polonini, Hudson C; Loures, da Silva Sharlene; Cerqueira, de Melo Victor Augusto; de, Andrade Laura; Fernandes, Brandão Marcos Antônio

Abstract

Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions

Author(s): de Oliveira Ferreira Anderson, Polonini Hudson C, Loures da Silva Sharlene, Cerqueira de Melo Victor Augusto, de Andrade Laura, Fernandes Brandão Marcos Antônio

Issue: May/Jun 2017 - Volume 21, Number 3

View All Articles in Issue

Page(s): 255-263

Download in electronic PDF format for $75

Abstract

The objective of this study was to evaluate the stability of 10 commonly used active pharmaceutical ingredients compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend SF PH4): alprazolam 1.0 mg/mL, atropine sulfate 0.1 mg/mL, glutamine 250.0 mg/mL, levofloxacin 50.0 mg/mL, metoprolol tartrate 10.0 mg/mL, nitrofurantoin 2.0 mg/mL, ondansetron hydrochloride 0.8 mg/mL, oxandrolone 3.0 mg/mL, pregabaline 20.0 mg/mL, riboflavin 10.0 mg/mL. All suspensions were stored at both controlled refrigeration (2°C to 8°C) and controlled room temperature (20°C to 25°C). Stability was assessed by measuring the percent recovery at varying time points throughout a 90-day period. Active pharmaceutical ingredients quantification was performed by high-performance liquid chromatography via a stability-indicating method. Given the percentage of recovery of the active pharmaceutical ingredients within the suspensions, the beyond-use date of the final products (active pharmaceutical ingredients + vehicle) was at least 90 days for all suspensions with regard to both temperatures. This suggests that the vehicle is stable for compounding active pharmaceutical ingredients from different pharmacological classes.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
May/Jun 2017 Pg. 255-263	Stability of Alprazolam, Atropine Sulfate, Glutamine, Levofloxacin, Metoprolol Tartrate, Nitrofurantoin, Ondansetron Hydrochloride, Oxandrolone, Pregabaline, and Riboflavin in SyrSpend SF pH4 Oral Suspensions Author(s): de Oliveira Ferreira Anderson, Polonini Hudson C, Loures da Silva Sharlene, Cerqueira de Melo Victor Augusto, de Andrade Laura, Fernandes Brandão Marcos Antônio
Sep/Oct 2021 Pg. 412	Atropine Sulfate 0.1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 2022 Pg. 140	Alprazolam 1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jan/Feb 2020 Pg. 55	Glutamine 250 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Nov/Dec 2021 Pg. 503	Metoprolol Tartrate 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Mar/Apr 1997 Pg. 125-127	Quantitation of Metoprolol Tartrate and Propranolol Hydrochloride in Pharmaceutical Dosage Forms: Stability of Metoprolol in an Aqueous Mixture Author(s): Gupta Vishnu D, Maswoswe J
Jan/Feb 2020 Pg. 60	Ondansetron Hydrochloride 0.8 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2020 Pg. 252-262	Stability of Azathioprine, Clonidine Hydrochloride, Clopidogrel Bisulfate, Ethambutol Hydrochloride, Griseofulvin, Hydralazine Hydrochloride, Nitrofurantoin, and Thioguanine Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, Loures da Silva Sharlene, Neves Cunha Carolina, de Oliveira Ferreira Anderson, Anagnostou Korina, Dijkers Eli
Jul/Aug 1997 Pg. 271-273	Atropine Overdosage with a Suppository Formulation Containing Atropine Sulfate Author(s): Allen Loyd V Jr
Mar/Apr 2020 Pg. 134	Nitrofurantoin 2 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2019 Pg. 410	Oxandrolone 3 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
May/Jun 2015 Pg. 242	Atropine Sulfate 1% Ophthalmic Solution Author(s): Allen Loyd V Jr
Nov/Dec 2019 Pg. 489	Riboflavin 10 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2020 Pg. 407	Levofloxacin 50 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Sep/Oct 2005 Pg. 394	Morphine Sulfate 16-mg and Atropine Sulfate 0.4-mg/mL Injection Author(s): Allen Loyd V Jr
Jan/Feb 2002 Pg. 66-69	Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Clonidine Hydrochloride Packaged in Plastic Syringes Author(s): Xu Quanyun A, Trissel Lawrence A, Pham Lien
Jan/Feb 2002 Pg. 70-73	Physical and Chemical Stability of Low and High Concentrations of Morphine Sulfate with Bupivacaine Hydrochloride Packaged in Plastic Syringes Author(s): Trissel Lawrence A, Xu Quanyun A, Pham Lien
Jul/Aug 2003 Pg. 300	Meperidine HCl 100-mg/mL and Atropine Sulfate 0.4-mg/mL Injection Author(s): Allen Loyd V Jr
Nov/Dec 2018 Pg. 516-526	Compatibility of Baclofen, Carvedilol, Hydrochlorothiazide, Mercaptopurine, Methadone Hydrochloride, Oseltamivir Phosphate, Phenobarbital, Propranolol Hydrochloride, Pyrazinamide, Sotalol Hydrochloride, Spironolactone, Tacrolimus Monohydrate, Ursodeoxycholic Acid, and Vancomycin Hydrochloride Oral Suspensions Compounded with SyrSpend SF pH4 Author(s): Polonini Hudson, da Silva Sharlene Loures, Brandão Marcos Antônio Fernandes, Bauters Tiene, De Moerloose Barbara, Ferreira Anderson de Oliveira
Jul/Aug 2017 Pg. 339-346	Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio